Whole tumor MR Perfusion histogram analysis in the preoperative assessment of patients with gliomas: Differentiation between high- and low-grade tumors

Purpose: To compare the diagnostic accuracy of normalized Blood Volume (nBV) histogram metrics in differentiating low from high-grade gliomas. Material and Methods: Forty-four patients (22 female, 22 male) with histologically confirmed gliomas were included. Group A comprised 10 patients with low grade gliomas (all grade II) while group B comprised 34 patients (4 grade III and 30 grade IV). Three-dimensional whole tumor segmentation was based on intensity level clustering in T2 FLAIR for the non-enhancing lesions or post contrast T1 weighted images for the enhancing lesions. Dynamic Susceptibility Contrast (DSC) perfusion was applied in all patients, and leakage corrected nBV maps were created. Corresponding histograms were generated from all the pixels included in the tumor volume. Minimum, maximum, mean, standard deviation, median, skewness, kurtosis, 5%, 30%, 70% and 95% percentiles, as well as normalized peak height and maximum peak position derived from normalized blood volume histograms were calculated for both groups. ROC analysis was performed to find optimum thresholds for differentiating between low and high grade gliomas. Results: 5% percentile of nBV normalized histogram provided the highest area under the curve (AUROC: 0.93) for the differentiation of low from high grade gliomas. A threshold value of 0.07 for the 5% percentile of nBV normalized histogram resulted in 90.8% sensitivity and 90% specificity. The positive and negative predictive values were 96.7% and 75%, respectively while the accuracy reached 91%. When removing 2 IDH mutation positive HGG patients, the corresponding AUROC increased to 0.98. Conclusion: Whole tumor normalized Blood Volume histogram analysis proved to be a very accurate method to differentiate low from high grade gliomas.

[1]  R R Edelman,et al.  Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. , 1990, Radiology.

[2]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[3]  C Tanaka,et al.  Discrimination of brain abscess from necrotic or cystic tumors by diffusion-weighted echo planar imaging. , 1996, Magnetic resonance imaging.

[4]  B R Rosen,et al.  Clinical applications of intracranial perfusion MR imaging. , 1999, Neuroimaging clinics of North America.

[5]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[6]  V. Jellús,et al.  Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. , 2001, AJNR. American journal of neuroradiology.

[7]  M. Kitajima,et al.  Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI , 2002, Neuroradiology.

[8]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[9]  Glyn Johnson,et al.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.

[10]  Michael H Lev,et al.  Dynamic magnetic resonance perfusion imaging of brain tumors. , 2004, The oncologist.

[11]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[12]  J. Guyotat,et al.  Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors , 2006, Neuroradiology.

[13]  I. Ercan,et al.  High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. , 2005, Clinical radiology.

[14]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[15]  Glyn Johnson,et al.  Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.

[16]  S. Y. Kim,et al.  A Prospective Study on the Added Value of Pulsed Arterial Spin-Labeling and Apparent Diffusion Coefficients in the Grading of Gliomas , 2007, American Journal of Neuroradiology.

[17]  Mitchel S Berger,et al.  Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. , 2007, Journal of neurosurgery.

[18]  P. Baraldi,et al.  Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging , 2007, Neuroradiology.

[19]  Elias R Melhem,et al.  Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience. , 2007, Radiology.

[20]  A. Bjørnerud,et al.  Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. , 2008, Radiology.

[21]  R. Agid,et al.  Preoperative Grading of Presumptive Low-Grade Astrocytomas on MR Imaging: Diagnostic Value of Minimum Apparent Diffusion Coefficient , 2008, American Journal of Neuroradiology.

[22]  A. Bjørnerud,et al.  Histogram Analysis of MR Imaging–Derived Cerebral Blood Volume Maps: Combined Glioma Grading and Identification of Low-Grade Oligodendroglial Subtypes , 2008, American Journal of Neuroradiology.

[23]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[24]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[25]  Soonmee Cha,et al.  Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy. , 2014, CNS oncology.